联合视网膜神经纤维层与神经节细胞内丛状层厚度的广域趋势进展分析:改善青光眼进展检测的新范式
这项前瞻性纵向研究纳入236例青光眼患者的440只眼和49名健康人的98只眼,每约4个月进行OCT和视野检查至少3年,采用广域趋势进展分析(假发现率控制在5%)评估RNFL、GCIPL及联合RNFL-GCIPL厚度进展。结果显示联合RNFL-GCIPL进展眼比例(28.9%)高于单独RNFL(16.8%)或GCIPL(5.9%),且联合进展眼发生可能或很可能视野进展的风险显著升高。
要点
- 联合RNFL-GCIPL广域趋势分析比单独RNFL或GCIPL检测到更多进展眼。
- 联合RNFL-GCIPL进展几乎总在单独RNFL或GCIPL进展之前或同时被检出。
- 联合RNFL-GCIPL进展眼发生可能视野进展的风险为无进展眼的2.4倍。
核心结论
- 联合RNFL-GCIPL厚度进展分析可识别出单独RNFL或GCIPL进展分析均未发现的进展眼。
- 广域RNFL-GCIPL厚度进展分析能有效提示青光眼患者视野进展风险。
研究设计与样本
- 前瞻性纵向研究,纳入236例青光眼患者的440只眼和49名健康人的98只眼。
- 每约4个月进行OCT RNFL/GCIPL/RNFL-GCIPL厚度和视野测量,随访至少3年。
- 采用广域(12×9 mm²)趋势进展分析,假发现率控制在5%。
- 视野进展采用早期青光眼 Manifest 试验(EMGT)标准判定。
主要发现
- 青光眼组中,联合RNFL-GCIPL进展眼127只(28.9%,95%CI:23.9%-33.8%),多于单独RNFL进展的74只(16.8%,95%CI:13.1%-20.6%)和单独GCIPL进展的26只(5.9%,95%CI:3.7%-8.1%)。
- 联合RNFL-GCIPL进展几乎总在单独RNFL或GCIPL进展之前或同时被检出。
- 健康组估计的趋势进展分析特异度:联合RNFL-GCIPL为83.7%(95%CI:74.9%-92.4%),RNFL为94.9%(95%CI:90.6%-99.2%),GCIPL为96.9%(95%CI:93.5%-100.0%)。
- 校正协变量后,联合RNFL-GCIPL进展眼发生可能视野进展的风险比(HR)为2.4(95%CI:1.2-5.0),很可能视野进展的HR为4.6(95%CI:1.5-14.0)。
关键数值与推荐
- 趋势进展分析假发现率控制在5%。
- 视野进展判定采用EMGT标准。
- 联合RNFL-GCIPL进展定义基于广域12×9 mm²范围内厚度趋势分析。
临床怎么用
- 在青光眼OCT随访中,可考虑联合RNFL-GCIPL广域趋势进展分析以提高进展检出率。
- 联合RNFL-GCIPL进展提示视野进展风险升高,可辅助临床加强监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Evaluation of glaucoma progression with OCT has been centered on the analysis of progressive retinal nerve fiber layer (RNFL) thinning over the parapapillary region and/or progressive ganglion cell inner plexiform layer (GCIPL) thinning over the macula. We investigated (1) whether combining the RNFL and GCIPL as a single layer (i.e., RNFL-GCIPL) for wide-field progression analysis outperforms wide-field progression analysis of the RNFL or the GCIPL, and (2) whether eyes with progressive RNFL-GCIPL thinning are at risk of visual field (VF) progression. DESIGN: Prospective, longitudinal study. PARTICIPANTS: A total of 440 eyes from 236 glaucoma patients; 98 eyes from 49 healthy individuals. METHODS: OCT RNFL/GCIPL/RNFL-GCIPL thickness and VF measurements were obtained at ∼4-month intervals for ≥3 years. Progressive changes of the RNFL/GCIPL/RNFL-GCIPL thicknesses were analyzed over a wide field (12×9 mm2) covering the parapapillary region and the macula with trend-based progression analysis (TPA) controlled at a false discovery rate of 5%. VF progression was determined by the Early Manifest Glaucoma Trial criteria. MAIN OUTCOME MEASURES: Proportions of eyes with progressive RNFL/GCIPL/RNFL-GCIPL thinning; hazard ratios (HRs) for development of VF progression. RESULTS: More eyes showed progressive RNFL-GCIPL thinning (127 eyes; 28.9%, 95% confidence interval [CI]: 23.9%-33.8%) than progressive RNFL thinning (74 eyes; 16.8%, 95% CI: 13.1%-20.6%) and progressive GCIPL thinning (26 eyes; 5.9%, 95% CI: 3.7%-8.1%) in the glaucoma group over the study follow-up. Progressive RNFL-GCIPL thinning was almost always detected before or simultaneously with progressive RNFL thinning or progressive GCIPL thinning. The specificity of TPA (estimated from the healthy group) for detection of progressive RNFL-GCIPL thinning, progressive RNFL thinning, and progressive GCIPL thinning was 83.7% (95% CI: 74.9%-92.4%), 94.9% (95% CI: 90.6%-99.2%), and 96.9% (95% CI: 93.5%-100.0%), respectively. Eyes with progressive RNFL-GCIPL thinning had a higher risk to develop possible (HR: 2.4, 95% CI: 1.2-5.0) or likely (HR: 4.6, 95% CI: 1.5-14.0) VF progression, with adjustment of covariates, compared with eyes without progressive RNFL-GCIPL thinning. CONCLUSIONS: Progression analysis of RNFL-GCIPL thickness reveals a significant portion of progressing eyes that neither progression analysis of RNFL thickness nor GCIPL thickness would identify. Wide-field progression analysis of RNFL-GCIPL thickness is effective to inform the risk of VF progression in glaucoma patients.
引用
- Wu K, Lin C, Lam AK, et al. Wide-field Trend-based Progression Analysis of Combined Retinal Nerve Fiber Layer and Ganglion Cell Inner Plexiform Layer Thickness: A New Paradigm to Improve Glaucoma Progression Detection. Ophthalmology. 2020. PMID: 32423768. doi:10.1016/j.ophtha.2020.03.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。